Labcorp
Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Name |
Synonyms |
Antibody Description/ Clinical Use |
---|---|---|
A-ACT |
Alpha-1 antichymotrypsin, A-ACT, ACT, A1AT |
α1-Antichymotrypsin; histiocytes; pancreatic pseudopapillary tumor |
A-AT |
Alpha-1-antitrypsin, A-AT |
α1-Antitrypsin; inherited A-AT deficiency |
ACTH |
Adrenocorticotropic hormone |
Antiadrenocorticotropic hormone; anterior pituitary |
Actin−Muscle-specific |
Muscle-specific actin, MSA, HHF-35 |
Skeletal, smooth, and cardiac muscle; myofibroblastic differentiation |
Actin−Smooth Muscle (SMA) |
Smooth muscle actin |
Myofibroblasts; myoepithelial cells |
AE1 |
Cytokeratin AE1 |
Cytokeratin AE1; epithelial marker |
AE1/AE3 |
Cytokeratin AE1/AE3 |
Screening cytokeratin cocktail; epithelial marker |
AE3 |
Cytokeratin AE3 |
Cytokeratin AE3; high molecular weight cytokeratin; epithelial marker |
AFP |
Alpha fetoprotein |
α-Fetoprotein (AFP); hepatocellular carcinoma; hepatoid carcinoma; yolk sac tumor |
AKT Phosphate |
RUO AKT 1; protein kinase B, PKB, Rac-alpha |
AKT (protein kinase B) |
ALK-1 |
Anaplastic lymphoma kinase-1 |
Anaplastic lymphoma kinase-1; anaplastic large-cell lymphoma; inflammatory myofibroblastic tumor; adenocarcinoma of lung subset |
Amyloid A |
Amyloid A protein |
|
Androgen Receptor |
AR |
Prostate carcinoma; associated with prognosis and treatment outcome |
Annexin A1 |
Annexin A, Annexin 1, ANXA1 |
Hairy cell leukemia; myeloid cells |
B72.3 |
TAG72, Breast-3,BRST-3 |
Simple epithelium; adenocarcinoma; excludes mesothelioma |
BCA-225 |
Breast carcinoma-associated glycoprotein |
Breast carcinoma-associated glycoprotein; breast carcinoma and other adenocarcinomas |
BCL-1 (Cyclin D1) |
Cyclin D1; PRAD-1 |
Mantle-cell lymphoma; multiple myeloma subset |
BCL-1/CD20 |
Double stain; useful for the diagnosis of mantle cell lymphoma |
|
BCL-2 |
Follicular lymphoma; other B-cell and T-cell lymphomas; soft tissue tumor |
|
BCL-2/BCL-6 |
Double stain; useful for the diagnosis of follicular center cell lymphoma, diffuse large-cell type |
|
BCL-6 |
Follicular center B-cells; follicular lymphoma; DLBCL subset |
|
Ber-EP4 |
BER-EP4, BerEP4, BEREP4, Ep-Cam, epithelial antigen, CD326, Ep-CAM |
Epithelial antigen; carcinoma; differentiates carcinoma from mesothelioma |
β-Amyloid |
Amyloid beta-protein (A-beta-P); amyloid beta-peptide; A-beta; beta-A4 protein; beta-protein |
Alzheimer's disease; senile plaques; neurofibrillary tangles; cerebrovascular deposits |
β-Catenin |
beta-catenin |
Soft tissue lesion; fibromatosis; synovial sarcoma |
BG8 (LewisY) |
Blood group-related antigen; Lewis Y |
Adenocarcinoma; exclude mesothelioma |
BOB-1 |
BOB.1/OBF.1 |
B-cells |
CA 19.9 |
CA-19.9 |
Pancreas, GI, ovary, lung, and transitional cell carcinoma |
CA 125 (OC125) |
OC125, ovarian cancer antigen |
Female genital tract; breast carcinoma; other adenocarcinoma, including lung and pancreatobiliary |
CAIX |
Carbonic anhydrase IX, CA9 |
Carbonic anhydrase IX; renal cell carcinoma (RCC); distinguish clear cell renal cell carcinoma from other RCC subset |
Calcitonin |
Thyroid C-cells; medullary carcinoma |
|
Caldesmon |
CALD, h-Caldesmon |
Smooth muscle and myoepithelial cells |
Calponin |
CALP |
Myoepithelial, myofibroblastic, and smooth muscle cells |
Calretinin |
CALRET |
Mesothelial cells; sex cord stromal tumor; adrenal cortical tumor |
CAM 5.2 |
CK8/18 |
Low molecular weight cytokeratin 8 and 18; epithelial tumor |
CAM 5.2/AE1 |
Screening cytokeratin cocktail; epithelial tumor |
|
CD1a |
Cortical thymocytes; Langerhans cell histiocytosis (LCH); T-ALL subset |
|
CD2 |
E-rosette receptor; LFA-2 |
Pan, thymic, and peripheral T-cells; NK cells; neoplastic mast cells |
CD3 (M) |
CD3 (mono) |
CD3 (monoclonal); pan T-cells |
CD3 (P) |
CD3 (poly) |
CD3 (polyclonal); pan T-cells |
CD3/CD20 |
Double stain; useful to distinguish B-cells (CD20+) and T-cells (CD3+) |
|
CD4 |
Helper/inducer T-cells; thymocyte and monocyte subsets |
|
CD5 |
Pan T-cells; B-cell lymphoma subset (B-CLL/SLL and MCL); thymic carcinoma |
|
CD7 |
Pan T‐cells; NK cells, thymocytes; rare AML |
|
CD8 |
Suppressor/cytotoxic T‐cells; thymocyte and T‐cell/NK cell subsets; T‐LGL leukemia |
|
CD10 |
CALLA |
CALLA; B-cell and T-cell lymphoma subsets; endometrial stromal cells; renal cell carcinoma subset |
CD14 |
Mature monocytes; some granulocytes; macrophages |
|
CD15 |
LeuM1 |
Epithelial, myeloid, and Reed-Sternberg cells; Hodgkin lymphoma |
CD20 |
L26 |
Pan B-cells |
CD21 |
Follicular dendritic cells; B-cell subset |
|
CD22 |
Pan B-cells |
|
CD23 |
BU38, SP23 |
Follicular dendritic cells; B-cell subset; B-CLL |
CD25 |
Activated T‐ and B‐cells; HCL; ATLL |
|
CD30 |
Ki-1, BerH2 |
Reed‐Sternberg cells; anaplastic large‐cell lymphoma; DLBCL subset; Hodgkin lymphoma; embryonal carcinoma |
CD31 |
PECAM, platelet-endothelial cell adhesion molecule-1 |
Endothelium; vascular neoplasm; plasma cells |
CD33 |
Monocytes; myeloid cells; AML; ALL subset |
|
CD34 |
Clones: QBEnd/10 and HPCA |
Blasts; stem cells; endothelium; GIST; soft tissue tumor subset |
CD35 |
Follicular dendritic cell marker; CR1 |
Follicular dendritic cells |
CD43 |
MT1 (T-cell) |
T-cells; B-cell lymphoma subset (B-CLL/SLL, MCL, Burkitt); plasma and myeloid cells; histiocytes |
CD45 (LCA) |
LCA, leukocyte-common antigen |
Leukocyte common antigen |
CD45RA |
CD45RA (B-cell marker) |
B-cells |
CD45RO |
CD45RO (T-cell marker), UCHL-1 |
Activated/memory T-cells; B-cell subset |
CD56 |
N-CAM, LEU-6 |
Neural and neuroendocrine tumor; soft tissue tumor subset; NK cells; plasma and T-cell subsets; LGL leukemia |
CD57 |
HNK‐1, LEU‐7 |
Neural and neuroendocrine tumor; thymoma; NK cells; T-LGL leukemia; T-cell subset |
CD61 |
GPIIIA |
Megakaryocytes; platelets |
CD68 |
KP-1 |
Histiocytes; macrophages |
CD71 |
Erythroid precursors and large-cell lymphoma; transferrin receptor; activated T- and B-cells; macrophages |
|
CD74 |
B-cells |
|
CD79a |
Pan B-cells |
|
CD99 |
MIC2, O13 |
PNET/Ewing sarcoma; soft tissue tumor subset; sex cord stromal tumor |
CD117 (c-KIT) |
CD117, c-KIT |
GIST; subset of carcinoma including adenoid cystic carcinoma; germ cell neoplasm; hematolymphoid neoplasm |
CD123 |
Dendritic cell precursors; type 2 (DC2) cells; blastic plasmacytoid dendritic cell neoplasm (BPDCN) |
|
CD138 |
Syndecan-1 |
Plasma cells; subset of epithelial cells |
CD163 |
M130, Ber-Mac3, Ki-M8, SM4 |
Monocytes; macrophages; dendritic interstitial cells |
CDX-2 |
Enteric differentiation; GI tumor; colorectal carcinoma; carcinoid tumor subset |
|
CDX-2/CK-7 |
Double stain; useful to distinguish stomach and colon carcinoma from breast, lung, and ovarian carcinoma |
|
CEA (M) |
Carcinoembryonic antigen (mono) |
Carcinoembryonic antigen (monoclonal); adenocarcinoma |
CEA (P) |
Carcinoembryonic antigen (poly) |
Carcinoembryonic antigen (polyclonal); epithelial marker; adenocarcinoma subset; negative in mesothelioma |
Chromogranin A |
CHROM |
Neuroendocrine neoplasm; paraganglioma |
Chymotrypsin |
Exocrine pancreas; acinar cell tumor |
|
CK-5 |
Cytokeratin 5 |
Tumor with squamous differentiation; squamous cell vs adenocarcinoma of lung classification; myoepithelial cells; benign vs malignant breast intraductal proliferation |
CK-5/6 |
Cytokeratin 5/6 |
Tumor with squamous differentiation; squamous cell vs adenocarcinoma of lung classification; myoepithelial cells; benign vs malignant breast intraductal proliferation |
CK-7 |
Cytokeratin 7 |
Various subtypes of carcinoma; frequently used in conjunction with CK-20 for tumor profiling |
CK-7/TTF-1 |
Double stain; useful for the diagnosis of lung adenocarcinoma |
|
CK-14 |
Cytokeratin 14 |
High molecular weight cytokeratin; tumor with squamous differentiation; myoepithelial cells; breast carcinoma with basal-like phenotype |
CK-17 |
Cytokeratin 17 |
High molecular weight cytokeratin; tumor with squamous differentiation; pancreatobiliary adenocarcinoma; breast carcinoma with basal-like phenotype |
CK-18 |
Cytokeratin 18 |
Low molecular weight cytokeratin |
CK-19 |
Cytokeratin 19 |
Epithelial tumor; papillary carcinoma of the thyroid vs benign thyroid lesion |
CK-20 |
Cytokeratin 20 |
Subset of carcinoma; reacts primarily with gastric and intestinal epithelium, urothelium, and Merkel cells |
CK-HMW (34βE12) |
Cytokeratin−high molecular weight, keratin 903, CK903, CK34bE12, 34betaE12 |
CK-903; broad-spectrum high molecular weight cytokeratin; squamous cell and subsets of adenocarcinoma and transitional cell carcinoma; prostate basal cells; prostate carcinoma vs adenosis/PIN |
CK-LMW (35βH11) |
Cytokeratin−low molecular weight, CK35bH11, CK8, 35betaH11 |
CK-8; epithelial neoplasm with simple epithelium |
CMV−IHC |
Cytomegalovirus by IHC |
Cytomegalovirus |
COLL-IV |
Collagen IV |
Collagen type IV; basement membrane material; soft tissue tumor subset |
COX-2 |
Cyclooxygenase-2 |
Cyclooxygenase-2; prognostic and predictive marker in a variety of tumors |
D2-40 |
Podoplanin |
Evaluation of lymphatic endothelial differentiation for lymphatic invasion; subset of angiosarcoma; vascular tumor of lymphatic origin; mesothelioma |
DBA44 (HCL) |
DBA.44, HCL |
Hairy cell leukemia |
Desmin |
DES |
Striated and smooth muscle; leiomyosarcoma; rhabdomyosarcoma; desmoplastic small round cell tumor |
DOG1 |
GIST, in particular CD117-negative lesion |
|
EBER−ISH |
EBV by ISH; Epstein-Barr virus |
Epstein-Barr early RNA; Epstein-Barr virus identification |
EBV (LMP1) |
Epstein-Barr virus |
Epstein-Barr virus; latent membrane protein |
E-Cadherin |
E-CAD |
Ductal vs lobular lesion of breast; positive in ductal lesion and negative in lobular neoplasia |
EGFR |
Epidermal growth factor receptor, erbB-1, HER-1, EGF-R |
Epidermal growth factor receptor; colon and lung carcinoma; basal-phenotype breast carcinoma |
EMA |
Epithelial membrane antigen, MAM6, MFGMP |
Epithelial membrane antigen; epithelial marker; subset of sarcoma, meningioma, and hematolymphoid neoplasm |
ER |
Estrogen receptor |
Estrogen receptor; predictive of endocrine therapy response in breast carcinoma; lower female genital tract carcinoma; endometrial stromal neoplasm; soft tissue lesion subset |
ERCC1 |
Excision repair cross-complementation group 1 |
Excision repair cross-complementation group 1; lung carcinoma; predictive indicator for cisplatin therapy |
Factor VIII (vWF) |
Von Willebrand factor, vWF |
Von Willebrand factor; endothelial marker; vascular neoplasm; blast cells in acute megakaryocytic leukemia |
Factor XIIIa |
Factor XIII, F13a |
Dermal dendrocytes and dendritic interstitial cells; used with CD34 to differentiate between dermatofibroma and dermatofibrosarcoma protuberans; fibrohistiocytic neoplasm |
Fascin |
Hodgkin and Reed-Sternberg cells |
|
FLI-1 |
Endothelial vascular cells/tumor; Ewing sarcoma/PNET; lymphoblastic lymphoma/leukemia |
|
FSH |
Follicle stimulating hormone |
Follicular-stimulating hormone; anterior pituitary |
Galectin-3 |
GAL3 |
Benign vs malignant thyroid follicular neoplasm, in particular papillary carcinoma |
Gastrin |
Gastric carcinoid; pancreatic endocrine neoplasm subset |
|
GCDFP-15 |
Gross cystic disease fluid protein 15, BRST-2 |
Gross cystic disease fluid protein-15; breast carcinoma; salivary and sweat gland neoplasm |
GFAP |
Glial fibrillary acidic protein |
Glial fibrillary acidic protein; glioma; lesion with glial differentiation; salivary gland tumor; neural neoplasm subset |
Glucagon |
GLU |
Pancreatic endocrine neoplasm |
Glycophorin A |
GPH-A |
Erythroid cells |
Glypican-3 |
GPC3 |
Hepatocellular carcinoma; germ cell tumor; yolk sac tumor |
Granzyme B |
Cytotoxic T-cell subset; NK cells |
|
Growth Hormone (GH) |
GH, hGH |
Growth hormone; anterior pituitary |
GST |
Glutathione S-transferase p, GST pi, GST P1 |
Distinguish Hodgkin disease and histiocytic malignancy from T-cell lymphoma |
HAM 56 |
HAM 56, anti-macrophage, macrophage |
Histiocytes |
HBME-1 |
Human mesothelial cell |
Mesothelial cells; subset of adenocarcinoma, in particular lower female genital tract origin; papillary carcinoma of the thyroid |
HBP (H. pylori) |
Helicobacter pylori, H. pylori, HBP |
Helicobacter pylori |
HCAg |
Hepatitis C antigen |
Hepatitis C antigen |
HCG |
Beta-HCG, B-HCG, human chorionic gonadotropin |
Human chorionic gonadotropin (beta); germ cell tumor; trophoblastic disease |
Hemoglobin A |
HgB A, HEMGL AF |
Red cell precursors |
HEP B CORE (HBcAg) |
Hepatitis B core antigen, HBVc, HBcAg |
Hepatitis B core antigen; hepatitis B |
HEP B SURF (HBsAg) |
Hepatitis B surface antigen, HBVs, HBsAg |
Hepatitis B surface antigen; hepatitis B |
HepPar 1 |
Hepatocyte |
Hepatocellular carcinoma; hepatoid tumor; germ cell tumor |
HER2 |
HER2/neu, c-erb2, Herceptest |
HER-2 protein overexpression; FDA-approved test for detection of HER2/neu; prognostic and predictive indicator in breast carcinoma |
Herpes I |
Herpes simplex virus 1 antigen, HSV-1 |
Herpes simplex virus type I |
Herpes II |
Herpes simplex virus II antigen, HSV-II |
Herpes simplex virus type II |
HHV-8 |
Human herpesvirus, type 8, HHV8 latent nuclear antigen, LNA |
Human herpesvirus 8; Kaposi’s sarcoma; primary effusion lymphoma |
HLA-DR |
HLA-DR |
Human leukocyte antigen; MHC class II antigen; B-cells; monocytes; myeloid cells; AML; ALL |
HMB-45 |
Melanosome |
Melanoma-associated marker; melanocytic lesion; pecoma |
HPL |
Human placental lactogen, human chorionic somatomammotropin |
Human placental lactogen; intermediate trophoblasts; placental site trophoblastic lesion |
HPV−IHC |
Human papilloma virus antigen, papillomavirus, HPV IHC |
Human papilloma virus |
HPV (6/11)−ISH |
Human papilloma virus |
Low-risk human papilloma virus subtypes |
HPV (16/18)−ISH |
Human papilloma virus |
High-risk human papilloma virus subtypes |
HPV (31/33)−ISH |
Human papilloma virus |
High-risk human papilloma virus subtypes |
HPV WSS−ISH |
Human papilloma virus |
Human papilloma virus wide screen; subtypes (6, 11, 16, 18, 30, 31, 33, 35, 45, 51, 52) |
HPV High−ISH |
Human papilloma virus, high risk by ISH, HPV III, HPV HR (16/18) |
Human papilloma virus probe cocktail; subtypes (16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 68, 70); types 16 and 18 are associated with cervical, vaginal, and vulvar malignancies |
HPV Low−ISH |
Human papilloma virus, low risk by ISH, HPV II, HPV LR (6/11) |
Human papilloma virus probe cocktail; subtypes (6, 11, 42, 43, 44); types 6 and 11 are associated with benign diseases (ie, genital warts) |
HPV High & Low−ISH |
Human papilloma virus, high risk and low risk by ISH |
Human papilloma virus high-and-low-probe cocktails; subtypes (6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, 56, 58, 59, 68, 70) |
IgA |
Immunoglobulin A, alpha-heavy chain |
Immunoglobulin A heavy chain |
IgD |
Immunoglobulin D, kappa-heavy chain |
Immunoglobulin D heavy chain |
IgG |
Immunoglobulin G, gamma-heavy chain |
Immunoglobulin G heavy chain |
IgG4 |
MRQ-44 |
IgG4-related sclerosing disease |
IgM |
Immunoglobulin M, mu-heavy chain |
Immunoglobulin M heavy chain |
Inhibin |
Inhibin alpha |
Sex cord stromal and adrenal cortical tumor; steroid lesion of the ovary |
Insulin |
Pancreatic endocrine neoplasm |
|
JC Virus−ISH |
JC (PML) |
Progressive multifocal leukoencephalopathy virus |
Kappa−IHC |
Kappa light chain immunoglobulin |
Immunoglobulin light chain; B-cells and plasma cells |
Kappa−ISH |
Kappa by ISH |
Immunoglobulin light chain; B-cells and plasma cells - RNA |
KER, PAN |
Pan-cytokeratin (AE1/AE3/PCK26), NY utilizes Pan-cytokeratin as AE1/AE3 |
Broad-spectrum cytokeratin cocktail |
Ki-67 |
Ki67 |
Cell proliferation marker |
Lambda−IHC |
Lambda light chain immunoglobulin |
Immunoglobulin light chain; B-cells and plasma cells |
Lambda−ISH |
Lambda by ISH |
Immunoglobulin light chain; B-cells and plasma cells - RNA |
LH |
Luteinizing hormone |
Luteinizing hormone; anterior pituitary |
Lipase |
Exocrine pancreas; acinar cell tumor |
|
Lysozyme (MURA) |
MURA, muramidase |
Muramidase; AML; granulocytic sarcoma; histiocytic differentiation |
Mammaglobin |
MAM |
Breast carcinoma; salivary gland lesion and sweat gland neoplasm |
MART-1 |
NY utilizes clone M2-7C10+M29E3 |
Melanoma-associated marker |
MBP |
Myelin basic protein |
Myelin basic protein; mucin; pancreatic carcinoma vs chronic pancreatitis; colorectal carcinoma; endometrial carcinoma; Barrett's esophagus |
M-Cell Tryptase |
Tryptase, mast cell tryptase |
Mast cells |
MEL-5 |
Melanoma-associated marker |
|
Melan-A |
MART-1, MELAN-AIS, NY utilizes clone A103 |
Melanoma-associated marker; melanocytic lesion and adrenal cortical neoplasm; pecoma |
Melan-A/Ki-67 |
Double stain; useful to distinguish malignant melanoma from benign melanocytic proliferation |
|
Mesothelin |
Meso |
Mesothelioma |
MiTF |
Microphthalmia associated transcription factor, MiTF |
Malignant melanoma; melanocytic lesion |
MLH-1 |
hMLH-1 |
DNA mismatch repair protein |
MOC-31 |
MOC-31, epithelial-related antigen |
Epithelial differentiation; adenocarcinoma vs mesothelioma |
MPO |
Myeloperoxidase, MPX |
Myeloperoxidase; AML; granulocytic sarcoma |
MSH-2 |
hMSH2 |
DNA mismatch repair protein |
MSH-6 |
hMSH6 |
DNA mismatch repair protein |
MUC1 |
Pancreatobiliary and extra-pancreatobiliary non-mucinous adenocarcinoma |
|
MUC2 |
Colorectal adenocarcinoma and mucinous adenocarcinoma of various sites |
|
MUC4 |
Epithelial tumor (breast, lung, cervix); pancreatic carcinoma |
|
MUC5AC |
Muc-5AC glycoprotein |
MUC5AC glycoprotein; distinguish primary mucinous ovarian tumor from colonic carcinoma metastatic to the ovary |
MUM-1 |
MUM1, IRF4, multiple myeloma 1, PIP |
Plasma cells; post-germinal B-cells; activated T-cells; Reed-Sternberg cells; DLBCL subset |
MYO DI |
MyoD1 |
Rhabdomyosarcoma |
Myogenin |
Rhabdomyosarcoma |
|
Myoglobin |
Rhabdomyosarcoma |
|
Myosin Heavy Chain |
SMM-HC, SMM, myosin smooth muscle |
Smooth-muscle myosin heavy chain; breast myoepithelial cells |
Napsin A |
NAPSA |
Lung adenocarcinoma |
NB84a |
Neuroblastoma tumor cells (for bone marrow aspirate and stem cell products, fresh specimen only) |
|
NEU-N |
Neuronal differentiation |
|
NF |
Neurofilament |
Neurofilament; Merkel cells and neural tumor |
NK1-C3 |
NK1/C3, NKI, melanoma-associated antigen |
Melanoma-associated marker; melanocytic lesion and neurothekeoma |
NPM |
Nucleophosmin |
Nucleophosmin; nucleophosmin mutations in AML |
NSE |
Neuron specific enolase |
Neuron-specific enolase; present in neurons and neuroendocrine cells (central and peripheral) |
OCT-2 |
B-cell lymphocyte transcription factor; B-cells |
|
OCT-3/4 |
Testicular germ cell tumor, in particular seminoma and embryonal carcinoma |
|
OSCAR |
Anti-cytokeratin (OSCAR) |
Broad-spectrum cytokeratin; epithelial lesion |
p16 |
p16, P16INK4A, MTS1, CDKN2 |
HPV-associated dysplasia/carcinoma (CINtec® p16INK4a) |
p21 |
p21, P21waf1, cip1, Sdi1, Pic1 |
Tumor suppressor gene |
p27/Kip1 |
p27, p27Kip1 |
Cyclin-dependent kinase inhibitor |
p53 |
p53 |
Mutated tumor suppressor gene |
p57 |
KIP2 |
Molar vs non-molar gestation; distinguish complete hydatidiform mole (CHM) from partial hydatidiform mole (PHM) and hydropic villi |
p63 |
p63 |
Prostatic basal cells; breast myoepithelial cells; squamous cell carcinoma |
p120 |
p120 catenin |
Ductal vs lobular breast lesion; lobular breast carcinoma |
P504S |
p504S, AMACR, racemase |
Prostatic carcinoma and high-grade PIN; subset of renal cell carcinoma |
Pan Melanoma |
NY/LA utilizes (HMB-45, MART-1, & Tyrosinase); IRV utilizes (MART-1, S100, & Tyrosinase) |
Melanoma and melanocytic lesion; pecoma |
PANC.POLY |
Pancreatic polypeptide, PP |
Pancreatic islet-cell tumor subset |
Parvovirus B19 |
Parvovirus B19, PVB19 |
Parvovirus |
PAX-2 |
Renal cell carcinoma |
|
PAX-5 |
PAX-5, Pan B-cell |
B-cell transcription factor; B-cells; Reed-Sternberg cells; subset of carcinoma including small-cell carcinoma |
PAX-5/CD43 |
Double stain; useful for the identification of CD43- coexpressing B-cell lymphoma |
|
PAX-5/CD5 |
Double stain; useful for the identification of CD5- coexpressing B-cell lymphoma |
|
PAX-8 |
Renal cell carcinoma |
|
PC (P. carinii) |
Pneumocystis carinii, P. carinii, PCP, PC |
Pneumocystis carinii |
PD1 |
Angio immunoblastic T-cell lymphoma (AITL); germinal center T-cells |
|
Perforin |
Lymphomas of cytotoxic or NK derivation |
|
PGP 9.5 |
Protein gene product 9.5 |
Protein gene product 9.5; neuroendocrine tumor |
PLAP |
Placental alkaline phosphatase |
Placental alkaline phosphatase; germ cell tumor; trophoblastic disease and subset of adenocarcinoma |
PMS-2 |
DNA mismatch repair protein |
|
PR |
Progesterone receptor, PgR |
Progesterone receptor; predictive of endocrine therapy response in breast carcinoma; lower female genital tract carcinoma; endometrial stromal neoplasm; soft tissue lesion subset |
Prolactin |
PL, PRO |
Anterior pituitary hormone |
PSA |
Prostate specific antigen |
Prostate-specific antigen; primary and metastatic prostatic neoplasm |
PSAP |
HPAP, PACP, prostatic acid phosphatase |
Prostatic acid phosphatase; primary and metastatic neoplasm; carcinoid tumor subset |
PSMA |
PSM, FOLH, GCP2 |
Prostate adenocarcinoma |
PTEN |
MMAC, TEP1 |
Cowden syndrome; carcinoma of the bladder, breast, endometrium, head and neck, kidney, lung, prostate, stomach, and thyroid; glioblastoma; melanoma |
PTH |
Parathyroid hormone |
Parathyroid hormone; parathyroid neoplasm |
PTS |
Prostate triple stain, TriView™ Prostate |
Prostate triple stain (P504S, p63, CK903); useful for the diagnosis of PIN/adenosis vs prostate carcinoma |
RB |
Retinoblastoma |
Retinoblastoma gene protein; retinoblastoma |
RCC (PNRA) |
RCC, PNRA, renal cell carcinoma antigen, gp200 |
Renal cell carcinoma |
S6 |
s6 |
Correlates with an increase in translation, particularly mRNAs with an oligopyrimidine tract |
S100 |
S-100 |
Neural tumor; melanoma; chondrocytes; epithelial neoplasm subset |
Serotonin |
SERO |
Carcinoid; pancreatic endocrine neoplasm |
Somatostatin |
SOMA |
Somatostatin; islet cell tumor; carcinoid; pancreatic endocrine neoplasm |
Surfactant (SP-A) |
SP-A, surfactant protein A, surfactant apoprotein A (SP-A), PE10 |
Surfactant protein A; lung adenocarcinoma |
Synaptophysin |
SYN |
Neural and neuroendocrine-derived tumor |
Synuclein |
Alpha-synuclein |
Neurodegenerative diseases (synucleinopathies); Parkinson's disease |
TAU |
Neurofibrillary tangles; Lewy bodies |
|
TCL-1 |
Ewing sarcoma/PNET; blastic plasmacytoid dendritic cell neoplasm (BPDCN) |
|
TCR β |
TCR beta F1 |
Alpha-beta T-cells |
TdT |
Terminal deoxynucleotidyl transferase |
Terminal deoxynucleotidyl transferase; cortical thymocytes; B-ALL; T-ALL |
Thrombomodulin |
CD141, TM, CD141, Thrombo |
Mesothelial cells; mesothelioma; lymphatic and vascular tumor |
Thyroglobulin |
THYRO, TGB |
Follicular and papillary carcinoma of the thyroid |
TIA-1 |
T-cell intracytoplasmic antigen |
T-cell intracytoplasmic antigen; cytotoxic T-cell subset |
TOXO |
Toxoplasma gondii, toxoplasmosis |
Toxoplasmosis |
TRAP |
Tartrate-resistant acid phosphatase |
Tartrate-resistant acid phosphatase; hairy cell leukemia |
TriView™ Breast |
Breast triple stain, breast microinvasion, CK5/p63/LMW |
Breast triple stain (CK5/p63/LMW); useful to differentiate DCIS from microinvasive breast carcinoma; differentiate radial scar from infiltrating carcinoma |
TriView™ Prostate |
PTS, PIN4, PIN 4 cocktail |
Prostate triple stain (P504S, p63, CK903); useful for the diagnosis of PIN/adenosis vs prostate carcinoma |
Trypsin |
Exocrine pancreas; acinar cell tumor |
|
TS |
Thymidylate synthase |
Thymidylate synthase; prognostic and predictive indicator for 5-FU-based chemotherapy in colorectal carcinoma |
TSH |
Thyroid stimulating hormone |
Thyroid-stimulating hormone; anterior pituitary |
TTF-1 |
Thyroid transcription factor-1, TTF |
Thyroid transcription factor-1; lung and thyroid carcinoma; subset of small cell carcinoma |
Tyrosinase |
Tyro |
Malignant melanoma; melanocytic lesion |
Ubiquitin |
Neurofibrillary tangles; Lewy bodies |
|
Uroplakin |
Uroplakin III, UPIII |
Urinary tract transitional cell carcinoma (primary and metastatic) |
VEGF |
Vascular endothelial growth factor, vascular permeability factor (VPF), VEGFR |
Vascular endothelial growth factor; stimulates endothelial cell proliferation; induces microvessel permeability; prognostic indicator |
Villin |
Differentiate gastrointestinal adenocarcinoma, neuroendocrine carcinoma, and ovarian adenocarcinoma from other adenocarcinoma; label Merkel cells of the skin |
|
Vimentin (VIM) |
Mesenchymal neoplasms; malignant melanoma and subsets of carcinoma and lymphoma |
|
VIP |
Vasoactive intestinal polypeptide |
Vasoactive intestinal polypeptide; pancreatic endocrine neoplasm |
VZV |
Varicella-Zoster virus |
Varicella-Zoster virus |
WT1 (M) N-Terminus |
Wilms' tumor protein |
Wilms' tumor protein; mesothelial cells; malignant mesothelioma; ovarian adenocarcinoma; sex cord stromal tumor of the ovary; endometrioid stromal neoplasm |
WT1 (P) C-Terminus |
Wilms' tumor protein |
Wilms' tumor protein carboxyl terminal; desmoplastic small round cell tumor |
ZAP-70 |
T-cells; CLL/SLL prognosis |
Frozen Gel Packs. To ensure specimen integrity during warm weather, follow these Instructions for Use of frozen gel packs and specimen lockboxes.